Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Scrip Awards
Partnered Content
Scrip Asia 100
Report Store
Ask The Analyst
PItCH
PDF Library
RSS Feeds
Subscribe
Advertise
UsernamePublicRestriction
Tags:
Deals Companies Reimbursement

EUSA CEO Says Divestment Gives It Funds, Clears Way For Cancer And Rare Disease Focus

  • Analysis

Executive Summary

By selling off its critical care business, EUSA Pharma gets needed funds and freedom to fully focus on oncology and rare diseases, its CEO tells Scrip.

You may also be interested in...



Asia Deal Watch: BeiGene Gets Chinese Rights To Two EUSA Rare Disease Therapies

BeiGene licenses antibody therapeutics for Castleman’s disease and high-risk neuroblastoma.

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.

Global AMR R&D Hub Launches Dynamic Data Dashboard

The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.

Table

View full table

Topics

Related Companies

Tags:
Deals Companies Reimbursement
UsernamePublicRestriction

Register

SC123403

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By